ArticleBritish journal of cancer2007
Dynamics of chemosensitivity and chromosomal instability in recurrent glioblastoma.
Article in British journal of cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05136326 (Multicenter Phase II Study of Preoperative Chemoradiotherapy With CApecitabine Plus Temozolomide in Patients With MGMT Silenced and Microsatellite Stable Locally Advanced RecTal Cancer), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multicenter Phase II Study of Preoperative Chemoradiotherapy With CApecitabine Plus Temozolomide in Patients With MGMT Silenced and Microsatellite Stable Locally Advanced RecTal Cancer: the CATARTIC Trial
Who cites it
19 citing papers in PubMed, 42 citations in OpenAlex.
- DNA Methylation and Transcript Variant Analysis ofInternational journal of molecular sciences · 2025Article
- Association of Intergenic and IntragenicInternational journal of molecular sciences · 2025Article
- Association ofCancers · 2023Article
- Association betweenCells · 2023Article
- Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness.Acta neuropathologica communications · 2022Article
- Discrimination between 34 of 36 Possible Combinations of Three C>T SNP Genotypes in theInternational journal of molecular sciences · 2021Article
- TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.Neuro-oncology · 2018Article
- Human tripartite motif protein 52 is required for cell context-dependent proliferation.Oncotarget · 2018Article
- Repeated photon and C-ion irradiations in vivo have different impact on alteration of tumor characteristics.Scientific reports · 2018Article
- Protein Analysis of Glioblastoma Primary and Posttreatment Pairs Suggests a Mesenchymal Shift at Recurrence.Journal of neuropathology and experimental neurology · 2016Article
- Temozolomide promotes genomic and phenotypic changes in glioblastoma cells.Cancer cell international · 2016Article
- Predictive value of the SLC22A18 protein expression in glioblastoma patients receiving temozolomide therapy.Journal of translational medicine · 2013Article
- Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO).Neuro-oncology · 2013Article
- Modeling evolutionary dynamics of epigenetic mutations in hierarchically organized tumors.PLoS computational biology · 2011Article
- Decoupling of DNA damage response signaling from DNA damages underlies temozolomide resistance in glioblastoma cells.Journal of biomedical research · 2010Article
- Different molecular patterns in glioblastoma multiforme subtypes upon recurrence.Journal of neuro-oncology · 2010Article
- O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients.Neuro-oncology · 2010Article
- Pharmacotherapy for adults with tumors of the central nervous system.Pharmacology & therapeutics · 2009Review
- FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities.Oncogene · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma multiforme is characterised by invasive growth and frequent recurrence. Here, we have analysed chromosomal changes in comparison to tumour cell aggressiveness and chemosensitivity of three cell lines established from a primary tumour and consecutive recurrences (BTL1 to BTL3) of a long-term surviving glioblastoma patient together with paraffin-embedded materials of five further cases with recurrent disease. Following surgery, the BTL patient progressed under irradiation/ lomustine but responded to temozolomide after re-operation to temozolomide. The primary tumour -derived BTL1 cells showed chromosomal imbalances typical of highly aggressive glioblastomas. Interestingly, BTL2 cells established from the first recurrence developed under therapy showed signs of enhanced chromosomal instability. In contrast, BTL3 cells from the second recurrence resembled a less aggressive subclone of the primary tumour. Although BTL2 cells exhibited a highly aggressive phenotype, BTL3 cells were characterised by reduced proliferative and migratory potential. Despite persistent methylation of the O6-methylguanine-DNA methyltransferase promoter, BTL3 cells exhibited the highest temozolomide sensitivity. A comparable situation was found in two out of five glioblastoma patients, both characterised by enhanced survival time, who also relapsed after surgery/chemotherapy with less aggressive recurrences. Taken together, our data suggest that pretreated glioblastoma patients may relapse with highly chemosensitive tumours confirming the feasibility of temozolomide treatment even in case of repeated recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.